Stacy Spears
Family · Sapulpa, OKNPI 1770572091
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 456 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Johnson & Johnson at 25.6% of the total. Among family clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 456 payments — averaging $27.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$3K
- Teva Pharmaceuticals USA, Inc.$2K
- Neurocrine Biosciences, Inc.$2K
- Otsuka America Pharmaceutical, Inc.$1K
- AbbVie$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- plus $2K from 15 others
What the payments were for
- Food & beverage$12,482100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 70 | $3,194 |
| Teva Pharmaceuticals USA, Inc. | 45 | $1,933 |
| Neurocrine Biosciences, Inc. | 75 | $1,515 |
| Otsuka America Pharmaceutical, Inc. | 47 | $1,345 |
| AbbVie | 103 | $1,339 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 49 | $1,302 |
| Alkermes, Inc. | 23 | $647 |
| Vanda Pharmaceuticals Inc. | 19 | $502 |
| E.r. Squibb & Sons, L.L.C. | 3 | $155 |
| Indivior Inc. | 6 | $114 |
| Supernus Pharmaceuticals, Inc. | 4 | $89 |
| Boehringer Ingelheim | 1 | $69 |
| Pear Therapeutics (US), Inc. | 1 | $59 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $47 |
| Exelixis Inc. | 2 | $37 |
| Corium, LLC | 1 | $33 |
| Harmony Biosciences LLC | 1 | $31 |
| Sunovion Pharmaceuticals Inc. | 2 | $28 |
| Lundbeck LLC | 1 | $21 |
| Boston Scientific | 1 | $19 |
| Lilly USA, LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVEGA SUSTENNA$2,140
- INVEGA TRINZA$1,391
- LYBALVI$855
- CAPLYTA$602
- Austedo XR$587
- INGREZZA$581
- REXULTI$474
- AUSTEDO$465
- VRAYLAR$351
- Fanapt$350
- SPRAVATO$252
- UZEDY$234
- COBENFY$122
- ABILIFY MAINTENA$111
How this compares
$12,496 in reported general payments places this provider in the 95th percentile of 2,026 family providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 41 | $295,807 |
| AustedoDeutetrabenazine | 30 | $208,329 |
| Invega SustennaPaliperidone Palmitate | 43 | $135,382 |
| VraylarCariprazine Hcl | 38 | $58,208 |
| RexultiBrexpiprazole | 19 | $50,250 |
| TrintellixVortioxetine Hydrobromide | 40 | $35,309 |
| LybalviOlanzapine/Samidorphan Malate | 23 | $34,639 |
| CaplytaLumateperone Tosylate | 16 | $26,622 |
| FanaptIloperidone | 12 | $21,929 |
| Aripiprazole | 50 | $4,257 |
| Lurasidone Hcl | 55 | $3,601 |
| Hydroxyzine Pamoate | 172 | $3,452 |
| Buspirone Hcl | 155 | $2,978 |
| Quetiapine Fumarate | 124 | $2,003 |
| Gabapentin | 121 | $1,994 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $1,933 | $504,13671 claims |
| Johnson & JohnsonInvega Sustenna | $3,194 | $135,38243 claims |
| AbbVieVraylar | $1,339 | $58,20838 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,345 | $50,25019 claims |
| Alkermes, Inc.Lybalvi | $647 | $34,63923 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,302 | $26,62216 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $502 | $21,92912 claims |
| Lilly USA, LLCOlanzapine | $17 | $83557 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,026 family providers in Oklahoma.
Other family in Sapulpa
- April WilcoxOklahoma City$245K
- Jeremy MorganOklahoma City$63K
- Samantha BellingerOklahoma City$39K
- Candy WilliamsTulsa$22K
- Lacey HillOklahoma City$20K
- Shelby WrightStillwater$17K
- Amanda OblanderYukon$17K
- Julia John SamuelOklahoma City$17K
- Jillian OakleafTulsa$15K
- Kristina SnyderOklahoma City$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.